The aryl hydrocarbon receptor (AhR) plays a role in the pathogenesis of psoriasis, and tapinarof, a novel, first‐in‐class, small molecule topical therapeutic AhR‐modulating agent has been recently approved by the FDA for the topical treatment of plaque psoriasis in adults. The gene discussed is AHR; the disease is psoriasis.